Small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up☆
Open accessThe DOI matches its Crossref record; 75 of the 75 references it cites were found in a registry or an index.
Abstract
A.-M. C. Dingemans, M. Früh, A. Ardizzoni, B. Besse, C. Faivre-Finn, L. E. Hendriks, S. Lantuejoul, S. Peters, N. Reguart, C. M. Rudin, D. De Ruysscher, P. E. Van Schil, J. Vansteenkiste & M. Reck, on behalf of the ESMO Guidelines Committee Department of Pulmonology, Erasmus MC Cancer Institute, University Medical Center Rotterdam, Department of Respiratory Medicine, Rotterdam; Department of Pulmonology, GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands; Department of Oncology and Haematology, Kantonsspital St. Gallen, St. Gallen; Department of Medical Oncology, University of Bern, Bern, Switzerland; Division of Medical Oncology, IRCCS Azienda Ospedaliero-Universitaria di Bologna, Bologna, Italy; Gustave Roussy, Villejuif; Paris-Saclay University, Orsay, France; Division of Cancer Sciences, University of Manchester & The Christie, NHS Foundation Trust, Manchester, UK; Department of Biopathology, Centre Léon Bérard, Grenoble Alpes University, Lyon, France; Department of Oncology, Centre Hospitalier Universitaire Vaudois, Lausanne University, Lausanne, Switzerland; Department of Medical Oncology, Hospital Clínic and Translational Genomics and Targeted Therapeutics in Solid Tumors, Institut d’Investigacions Biomèdiques August Pi i Sunyer (IDIBAPS), Barcelona, Spain; Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, USA; Department of Radiation Oncology (Maastro Clinic), GROW School for Oncology and Developmental Biology, Maastricht University Medical Center, Maastricht, The Netherlands; Department of Thoracic and Vascular Surgery, Antwerp University Hospital and University of Antwerp, Edegem, Belgium; Department of Respiratory Oncology, University Hospital KU Leuven, Leuven, Belgium; Department of Thoracic Oncology, Airway Research Center North, German Center for Lung Research, Lung Clinic, Grosshansdorf, Germany
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
First-line atezolizumab plus chemotherapy in extensive-stage small-cell lung cancer
Horn, L., Mansfield, A. S., Szczęsna, A., Havel, L., Krzakowski, M., Hochmair, M. J., Huemer, F., Losonczy, G., Johnson, M. L., Nishio, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809064 · Cited by 3,586
Self-citationOverall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC
Antonia, S. J., Villegas, A., Daniel, D., Vicente, D., Murakami, S., Hui, R., Kurata, T., Chiappori, A., Lee, K. H., de Wit, M., et al. (2018) · New England Journal of Medicine · doi:10.1056/nejmoa1809697 · Cited by 2,798
Self-citationMarabelle, A., Fakih, M., Lopez, J., Shah, M., Shapira-Frommer, R., Nakagawa, K., Chung, H. C., Kindler, H. L., Lopez-Martin, J. A., Miller, W. H., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30445-9 · Cited by 2,552 · cited 1×
“In addition, in KEYNOTE-158, an open-label, singlearm phase II study in advanced solid tumours, 76 SCLC patients who had failed standard first-line treatment (cohort G) were treated with pembrolizumab 200 mg every 3 weeks.(72) ORR was 18.”
BackgroundYu, H. A., Arcila, M. E., Rekhtman, N., Sima, C. S., Zakowski, M. F., Pao, W., Kris, M. G., Miller, V. A., Ladanyi, M., & Riely, G. J. (2013) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-12-2246 · Cited by 2,454 · cited 1×
“SCLC transformation is a known resistance mechanism in patients with epidermal growth factor receptor (EGFR)mutated NSCLC who are treated with EGFR tyrosine kinase inhibitors.(89) It occurs in 3%-5% of patients, especially in the presence of co-occurring RB1 and TP53 mutations.”
BackgroundPostmus, P. E., Kerr, K. M., Oudkerk, M., Senan, S., Waller, D. A., Vansteenkiste, J., Escriu, C., & Peters, S. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx222 · Cited by 2,302
Self-citationPaz-Ares, L., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2019) · The Lancet · doi:10.1016/s0140-6736(19)32222-6 · Cited by 2,298
Govindan, R., Page, N., Morgensztern, D., Read, W., Tierney, R., Vlahiotis, A., Spitznagel, E. L., & Piccirillo, J. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.4859 · Cited by 1,845
Prophylactic Cranial Irradiation for Patients with Small-Cell Lung Cancer in Complete Remission
Aupérin, A., Arriagada, R., Pignon, J.-P., Le Péchoux, C., Gregor, A., Stephens, R. J., Kristjansen, P. E. G., Johnson, B. E., Ueoka, H., Wagner, H., et al. (1999) · New England Journal of Medicine · doi:10.1056/nejm199908123410703 · Cited by 1,718
Turrisi, A. T., Kim, K., Blum, R., Sause, W. T., Livingston, R. B., Komaki, R., Wagner, H., Aisner, S., & Johnson, D. H. (1999) · New England Journal of Medicine · doi:10.1056/nejm199901283400403 · Cited by 1,506
Noda, K., Nishiwaki, Y., Kawahara, M., Negoro, S., Sugiura, T., Yokoyama, A., Fukuoka, M., Mori, K., Watanabe, K., Tamura, T., et al. (2002) · New England Journal of Medicine · doi:10.1056/nejmoa003034 · Cited by 1,371
Antonia, S. J., López-Martin, J. A., Bendell, J., Ott, P. A., Taylor, M., Eder, J. P., Jäger, D., Pietanza, M. C., Le, D. T., de Braud, F., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30098-5 · Cited by 1,244 · cited 1×
“2% in the highest tertile of tumours classified by TMB, with a median OS of 22 months.(77,78) Preliminary results from the phase II BALTIC study evaluating the combination of durvalumab and tremelimumab in platinum-refractory or -resistant stage IV SCLC showed similar results with an ORR of 9.”
ResultProphylactic Cranial Irradiation in Extensive Small-Cell Lung Cancer
Slotman, B., Faivre-Finn, C., Kramer, G., Rankin, E., Snee, M., Hatton, M., Postmus, P., Collette, L., Musat, E., & Senan, S. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa071780 · Cited by 1,133
Self-citationvon Pawel, J., Schiller, J. H., Shepherd, F. A., Fields, S. Z., Kleisbauer, J. P., Chrysson, N. G., Stewart, D. J., Clark, P. I., Palmer, M. C., Depierre, A., et al. (1999) · Journal of Clinical Oncology · doi:10.1200/jco.1999.17.2.658 · Cited by 968
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2018) · Cancer Cell · doi:10.1016/j.ccell.2018.04.001 · Cited by 893
De Ruysscher, D., Niedermann, G., Burnet, N. G., Siva, S., Lee, A. W. M., & Hegi-Johnson, F. (2019) · Nature Reviews Disease Primers · doi:10.1038/s41572-019-0064-5 · Cited by 868
Self-citationLiu, S. V., Reck, M., Mansfield, A. S., Mok, T., Scherpereel, A., Reinmuth, N., Garassino, M. C., De Castro Carpeno, J., Califano, R., Nishio, M., et al. (2021) · Journal of Clinical Oncology · doi:10.1200/jco.20.01055 · Cited by 862
Self-citationRudin, C. M., Awad, M. M., Navarro, A., Gottfried, M., Peters, S., Csőszi, T., Cheema, P. K., Rodriguez-Abreu, D., Wollner, M., Yang, J. C.-H., et al. (2020) · Journal of Clinical Oncology · doi:10.1200/jco.20.00793 · Cited by 760 · cited 5×
“In the recently reported KEYNOTE-604 trial, patients with extensive stage IV SCLC were randomised to receive platinum (carboplatin AUC 5 or cisplatin 75 mg/m(2), day 1) and etoposide (100 mg/m(2), days 1-3) with either pembrolizumab 200 mg or placebo for four cycles followed by pembrolizumab or placebo as maintenance…”
BackgroundMethodInfluentialSelf-citationParsons, A., Daley, A., Begh, R., & Aveyard, P. (2010) · BMJ · doi:10.1136/bmj.b5569 · Cited by 696
Goldman, J. W., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., et al. (2021) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30539-8 · Cited by 688
Self-citationHanna, N., Bunn, P. A., Langer, C., Einhorn, L., Guthrie, T., Beck, T., Ansari, R., Ellis, P., Byrne, M., Morrison, M., et al. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2005.04.8595 · Cited by 681
O'Brien, M. E. R., Ciuleanu, T.-E., Tsekov, H., Shparyk, Y., Čučeviá, B., Juhasz, G., Thatcher, N., Ross, G. A., Dane, G. C., & Crofts, T. (2006) · Journal of Clinical Oncology · doi:10.1200/jco.2006.06.5821 · Cited by 649
ESMO-magnitude of clinical benefit scale version 1.1
Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J.-Y., Tabernero, J., Zielinski, C., Piccart, M. J., & de Vries, E. G. E. (2017) · Annals of Oncology · doi:10.1093/annonc/mdx310 · Cited by 641
Dykewicz, C. A. (2001) · Clinical Infectious Diseases · doi:10.1086/321805 · Cited by 636
Mishima, S., Nozaki, Y., Mikami, S., Kihira, E., Iikura, M., Koketsu, R., Sugiyama, H., Masuda, T., Kaname, H., Egami, Y., et al. (2015) · Case Reports in Gastroenterology · doi:10.1159/000381140 · Cited by 631
Slotman, B. J., van Tinteren, H., Praag, J. O., Knegjens, J. L., El Sharouni, S. Y., Hatton, M., Keijser, A., Faivre-Finn, C., & Senan, S. (2015) · The Lancet · doi:10.1016/s0140-6736(14)61085-0 · Cited by 604
Self-citationFaivre-Finn, C., Snee, M., Ashcroft, L., Appel, W., Barlesi, F., Bhatnagar, A., Bezjak, A., Cardenal, F., Fournel, P., Harden, S., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30318-2 · Cited by 592
Self-citationRossi, A., Di Maio, M., Chiodini, P., Rudd, R. M., Okamoto, H., Skarlos, D. V., Früh, M., Qian, W., Tamura, T., Samantas, E., et al. (2012) · Journal of Clinical Oncology · doi:10.1200/jco.2011.40.4905 · Cited by 570
Self-citationResults of the Two Incidence Screenings in the National Lung Screening Trial
Aberle, D. R., DeMello, S., Berg, C. D., Black, W. C., Brewer, B., Church, T. R., Clingan, K. L., Duan, F., Fagerstrom, R. M., Gareen, I. F., et al. (2013) · New England Journal of Medicine · doi:10.1056/nejmoa1208962 · Cited by 550
Takahashi, T., Yamanaka, T., Seto, T., Harada, H., Nokihara, H., Saka, H., Nishio, M., Kaneda, H., Takayama, K., Ishimoto, O., et al. (2017) · The Lancet Oncology · doi:10.1016/s1470-2045(17)30230-9 · Cited by 549
Shepherd, F. A., Crowley, J., Van Houtte, P., Postmus, P. E., Carney, D., Chansky, K., Shaikh, Z., & Goldstraw, P. (2007) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31815bdc0d · Cited by 548
Reck, M., Luft, A., Szczesna, A., Havel, L., Kim, S.-W., Akerley, W., Pietanza, M. C., Wu, Y.-L., Zielinski, C., Thomas, M., et al. (2016) · Journal of Clinical Oncology · doi:10.1200/jco.2016.67.6601 · Cited by 538
Self-citationOtt, P. A., Elez, E., Hiret, S., Kim, D.-W., Morosky, A., Saraf, S., Piperdi, B., & Mehnert, J. M. (2017) · Journal of Clinical Oncology · doi:10.1200/jco.2017.72.5069 · Cited by 521
Marcoux, N., Gettinger, S. N., O’Kane, G., Arbour, K. C., Neal, J. W., Husain, H., Evans, T. L., Brahmer, J. R., Muzikansky, A., Bonomi, P. D., et al. (2019) · Journal of Clinical Oncology · doi:10.1200/jco.18.01585 · Cited by 500 · cited 1×
“4 months.(91) Of 20 patients who were treated with a taxane, 10 (50%) had a response.”
BackgroundComplete resection in lung cancer surgery: proposed definition
Rami-Porta, R., Wittekind, C., & Goldstraw, P. (2005) · Lung Cancer · doi:10.1016/j.lungcan.2005.01.001 · Cited by 495
Trigo, J., Subbiah, V., Besse, B., Moreno, V., López, R., Sala, M. A., Peters, S., Ponce, S., Fernández, C., Alfaro, V., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30068-1 · Cited by 486
Self-citationOffin, M., Chan, J. M., Tenet, M., Rizvi, H. A., Shen, R., Riely, G. J., Rekhtman, N., Daneshbod, Y., Quintanal-Villalonga, A., Penson, A., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.06.002 · Cited by 444
Self-citationNicholson, A. G., Chansky, K., Crowley, J., Beyruti, R., Kubota, K., Turrisi, A., Eberhardt, W. E. E., van Meerbeeck, J., Rami-Porta, R., Goldstraw, P., et al. (2016) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.008 · Cited by 421
Self-citationEckardt, J. R., von Pawel, J., Pujol, J.-L., Papai, Z., Quoix, E., Ardizzoni, A., Poulin, R., Preston, A. J., Dane, G., & Ross, G. (2007) · Journal of Clinical Oncology · doi:10.1200/jco.2006.08.3998 · Cited by 393
Self-citationGregor, A., Cull, A., Stephens, R. J., Kirkpatrick, J. A., Yarnold, J. R., Girling, D. J., Macbeth, F. R., Stout, R., & Machin, D. (1997) · European Journal of Cancer · doi:10.1016/s0959-8049(97)00135-4 · Cited by 371
von Pawel, J., Jotte, R., Spigel, D. R., O'Brien, M. E. R., Socinski, M. A., Mezger, J., Steins, M., Bosquée, L., Bubis, J., Nackaerts, K., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2013.54.5392 · Cited by 352
Self-citationThird-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Ready, N., Farago, A. F., de Braud, F., Atmaca, A., Hellmann, M. D., Schneider, J. G., Spigel, D. R., Moreno, V., Chau, I., Hann, C. L., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2018.10.003 · Cited by 344
Morgensztern, D., Besse, B., Greillier, L., Santana-Davila, R., Ready, N., Hann, C. L., Glisson, B. S., Farago, A. F., Dowlati, A., Rudin, C. M., et al. (2019) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-19-1133 · Cited by 326
Self-citationWolfson, A. H., Bae, K., Komaki, R., Meyers, C., Movsas, B., Le Pechoux, C., Werner-Wasik, M., Videtic, G. M. M., Garces, Y. I., & Choy, H. (2011) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2010.05.013 · Cited by 283
Mascaux, C., Paesmans, M., Berghmans, T., Branle, F., Lafitte, J. J., Lemaı̂tre, F., Meert, A. P., Vermylen, P., & Sculier, J. P. (2000) · Lung Cancer · doi:10.1016/s0169-5002(00)00127-6 · Cited by 270 · cited 2×
“For decades, a platinum plus etoposide has been the preferred first-line treatment for extensive-stage SCLC, with a median OS of 9-10 months, PFS of 5-6 months and 1-year OS of w35% [I, A].(26) A meta-analysis of individual patient data showed no difference in OS between cisplatin and carboplatin.”
BackgroundSecond-line nivolumab in relapsed small-cell lung cancer: CheckMate 331☆
Spigel, D. R., Vicente, D., Ciuleanu, T. E., Gettinger, S., Peters, S., Horn, L., Audigier-Valette, C., Pardo Aranda, N., Juan-Vidal, O., Cheng, Y., et al. (2021) · Annals of Oncology · doi:10.1016/j.annonc.2021.01.071 · Cited by 270
Self-citationPurpose of Quality Standards for Infectious Diseases
Gross, P. A., Barrett, T. L., Dellinger, E. P., Krause, P. J., Martone, W. J., McGowan, J. E., Sweet, R. L., & Wenzel, R. P. (1994) · Clinical Infectious Diseases · doi:10.1093/clinids/18.3.421 · Cited by 223
Baize, N., Monnet, I., Greillier, L., Geier, M., Léna, H., Janicot, H., Vergnenégre, A., Créquit, J., Lamy, R., Auliac, J. B., et al. (2020) · The Lancet Oncology · doi:10.1016/s1470-2045(20)30461-7 · Cited by 204
Hellmann, M. D., Callahan, M. K., Awad, M. M., Calvo, E., Ascierto, P. A., Atmaca, A., Rizvi, N. A., Hirsch, F. R., Selvaggi, G., Szustakowski, J. D., et al. (2019) · Cancer Cell · doi:10.1016/j.ccell.2019.01.011 · Cited by 196
Bunn, P. A., Crowley, J., Kelly, K., Hazuka, M. B., Beasley, K., Upchurch, C., Livingston, R., Weiss, G. R., Hicks, W. J., & Gandara, D. R. (1995) · Journal of Clinical Oncology · doi:10.1200/jco.1995.13.7.1632 · Cited by 190
A phase II study of paclitaxel in heavily pretreated patients with small-cell lung cancer
Smit, E., Fokkema, E., Biesma, B., Groen, H., Snoek, W., & Postmus, P. (1998) · British Journal of Cancer · doi:10.1038/bjc.1998.54 · Cited by 190
Le Péchoux, C., Laplanche, A., Faivre-Finn, C., Ciuleanu, T., Wanders, R., Lerouge, D., Keus, R., Hatton, M., Videtic, G. M., Senan, S., et al. (2011) · Annals of Oncology · doi:10.1093/annonc/mdq576 · Cited by 190
Self-citationSeute, T., Leffers, P., ten Velde, G. P. M., & Twijnstra, A. (2008) · Cancer · doi:10.1002/cncr.23361 · Cited by 188
Pietanza, M. C., Kadota, K., Huberman, K., Sima, C. S., Fiore, J. J., Sumner, D. K., Travis, W. D., Heguy, A., Ginsberg, M. S., Holodny, A. I., et al. (2012) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-11-2059 · Cited by 188
Pujol, J.-L., Greillier, L., Audigier-Valette, C., Moro-Sibilot, D., Uwer, L., Hureaux, J., Guisier, F., Carmier, D., Madelaine, J., Otto, J., et al. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.008 · Cited by 179
Owonikoko, T. K., Behera, M., Chen, Z., Bhimani, C., Curran, W. J., Khuri, F. R., & Ramalingam, S. S. (2012) · Journal of Thoracic Oncology · doi:10.1097/jto.0b013e31824c7f4b · Cited by 163
Goto, K., Ohe, Y., Shibata, T., Seto, T., Takahashi, T., Nakagawa, K., Tanaka, H., Takeda, K., Nishio, M., Mori, K., et al. (2016) · The Lancet Oncology · doi:10.1016/s1470-2045(16)30104-8 · Cited by 155
Paraneoplastic neurologic disorders in small cell lung carcinoma: A prospective study
Gozzard, P., Woodhall, M. R., Chapman, C. J., Nibber, A., Waters, P. J., Vincent, A. C., Lang, B., & Maddison, P. (2015) · Neurology · doi:10.1212/wnl.0000000000001721 · Cited by 134
Prognostic factors differ by tumor stage for small cell lung cancer
Foster, N. R., Mandrekar, S. J., Schild, S. E., Nelson, G. D., Rowland, K. M., Deming, R. L., Kozelsky, T. F., Marks, R. S., Jett, J. R., & Adjei, A. A. (2009) · Cancer · doi:10.1002/cncr.24314 · Cited by 128
Surgical Resection of SCLC: Prognostic Factors and the Tumor Microenvironment
Zhao, X., Kallakury, B., Chahine, J. J., Hartmann, D., Zhang, Y., Chen, Y., Zhang, H., Zhang, B., Wang, C., & Giaccone, G. (2019) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2019.01.019 · Cited by 109
Tobacco Cessation May Improve Lung Cancer Patient Survival
Amato, K. A., Hyland, A. J., Reed, R., Mahoney, M. C., Marshall, J. R., Giovino, G. A., Bansal‐Travers, M., Ochs‐Balcom, H. M., Zevon, M. A., Cummings, K. M., et al. (2015) · Journal of Thoracic Oncology · doi:10.1097/jto.0000000000000578 · Cited by 107
Comorbidity in Patients With Small-Cell Lung Cancer: Trends and Prognostic Impact
Aarts, M. J., Aerts, J. G. J. V., van den Borne, B. E., Biesma, B., Lemmens, V. E. P. P., & Kloover, J. S. (2014) · Clinical Lung Cancer · doi:10.1016/j.cllc.2014.12.003 · Cited by 91
Surgery for limited-stage small-cell lung cancer
Barnes, H., See, K., Barnett, S. A., & Manser, R. L. (2017) · Cochrane Database of Systematic Reviews · doi:10.1002/14651858.cd011917.pub2 · Cited by 89
Rossi, A., Garassino, M. C., Cinquini, M., Sburlati, P., Maïo, M. D., Farina, G., Gridelli, C., & Torri, V. (2010) · Lung Cancer · doi:10.1016/j.lungcan.2010.02.001 · Cited by 79
Phase II study of weekly paclitaxel for relapsed and refractory small cell lung cancer.
Yamamoto, N., Tsurutani, J., Yoshimura, N., Asai, G., Moriyama, A., Nakagawa, K., Kudoh, S., Takada, M., Minato, Y., & Fukuoka, M. (2006) · PubMed · Cited by 79
Effect of cigarette smoking on quality of life in small cell lung cancer patients
Chen, J., Qi, Y., Wampfler, J. A., Jatoi, A., Garces, Y. I., Busta, A. J., Mandrekar, S. J., & Yang, P. (2012) · European Journal of Cancer · doi:10.1016/j.ejca.2011.12.002 · Cited by 78
Martucci, F., Pascale, M., Valli, M. C., Pesce, G. A., Froesch, P., Giovanella, L., Richetti, A., & Treglia, G. (2020) · Frontiers in Medicine · doi:10.3389/fmed.2019.00336 · Cited by 73
Lee, S. M., James, L. E., Qian, W., Spiro, S. G., Eisen, T. G., Gower, N. H., Ferry, D., Gilligan, D., Harper, P., Prendiville, J., et al. (2008) · Thorax · doi:10.1136/thx.2007.093872 · Cited by 66
Goldman, J. W., Garassino, M. C., Chen, Y., Özgüroğlu, M., Dvorkin, M. V., Trukhin, D. V., Statsenko, G., Hotta, K., Ji, J. H., Hochmair, M. J., et al. (2020) · Lung Cancer · doi:10.1016/j.lungcan.2020.09.003 · Cited by 64
Screening with Low-Dose Computed Tomography Does Not Improve Survival of Small Cell Lung Cancer
Silva, M., Galeone, C., Sverzellati, N., Marchianò, A. V., Calareso, G., Sestini, S., Vecchia, C. L., Sozzi, G., Pelosi, G., & Pastorino, U. (2015) · Journal of Thoracic Oncology · doi:10.1016/j.jtho.2015.10.014 · Cited by 58
Zauderer, M. G., Drilon, A., Kadota, K., Huberman, K. H., Sima, C. S., Bergagnini, I., Sumner, D. K., Travis, W. D., Heguy, A., Ginsberg, M. S., et al. (2014) · Lung Cancer · doi:10.1016/j.lungcan.2014.08.007 · Cited by 57
Karam, I., Jiang, S. Y., Khaira, M., Lee, C. W., & Schellenberg, D. D. (2013) · American Journal of Clinical Oncology · doi:10.1097/coc.0b013e31828aab2a · Cited by 44
Stinchcombe, T. E. (2017) · The Oncologist · doi:10.1634/theoncologist.2017-0204 · Cited by 38
Bondarenko, I., Juan, Ó., Pajkos, G., Kryzhanivska, A., Székely, Z. P., Vicente, D., Vynnychenko, I. O., Jones, S., Wang, Y., Jiang, H., et al. (2018) · Annals of Oncology · doi:10.1093/annonc/mdy298.001 · Cited by 37
Ferris, M. J., Jiang, R., Behera, M., Ramalingam, S. S., Curran, W. J., & Higgins, K. A. (2018) · International Journal of Radiation Oncology*Biology*Physics · doi:10.1016/j.ijrobp.2018.05.066 · Cited by 19
Recent Survival Trends in High-Grade Neuroendocrine Neoplasms and Lung Cancer
Breitling, L. P., Rinke, A., & Gress, T. M. (2019) · Neuroendocrinology · doi:10.1159/000500883 · Cited by 12
Cited by
Small Cell Lung Cancer, Version 2.2022, NCCN Clinical Practice Guidelines in Oncology
Ganti, A. K. P., Loo, B. W., Bassetti, M., Blakely, C., Chiang, A., D'Amico, T. A., D'Avella, C., Dowlati, A., Downey, R. J., Edelman, M., et al. (2021) · Journal of the National Comprehensive Cancer Network · doi:10.6004/jnccn.2021.0058 · Cited by 486
Megyesfalvi, Z., Gay, C. M., Popper, H., Pirker, R., Ostoros, G., Heeke, S., Lang, C., Hoetzenecker, K., Schwendenwein, A., Boettiger, K., et al. (2023) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.21785 · Cited by 369
Durvalumab after Chemoradiotherapy in Limited-Stage Small-Cell Lung Cancer
Cheng, Y., Spigel, D. R., Cho, B. C., Laktionov, K. K., Fang, J., Chen, Y., Zenke, Y., Lee, K. H., Wang, Q., Navarro, A., et al. (2024) · New England Journal of Medicine · doi:10.1056/nejmoa2404873 · Cited by 358
Metadata
- Authors
- Dingemans, A.-M. C., Früh, M., Ardizzoni, A., Besse, B., Faivre-Finn, C., Hendriks, L. E., Lantuejoul, S., Peters, S., Reguart, N., Rudin, C. M., De Ruysscher, D., Van Schil, P. E., Vansteenkiste, J., & Reck, M.
- Venue
- Annals of Oncology
- Publisher
- Elsevier BV
- Published
- 2021-07
- Volume
- 32
- Issue
- 7
- Pages
- 839-853
- ISSN
- 0923-7534 (ISSN-L)
- OpenAlex
- W3155388144
- Cited by
- 626
- References
- 75
- FWCI
- 28.37
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.